Skip to content
10-K

Annual Report

NRX Pharmaceuticals, Inc. NRXP

0001437749-26-009418

← back to feed
Filed
Mar 23, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 23, 2026 33.07M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$14.11M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$10.64M
Cash And Equivalents FY 2025 · Dec 31, 2025 $7.8M
Cash And Equivalents FY 2025 · Dec 31, 2024 $1.44M
Stockholders Equity FY 2025 · Dec 31, 2025 −$15.94M
Stockholders Equity FY 2025 · Dec 31, 2024 −$23.22M
Stockholders Equity FY 2025 · Dec 31, 2023 −$11.73M
Current Liabilities FY 2025 · Dec 31, 2025 $28.58M
Current Liabilities FY 2025 · Dec 31, 2024 $21.86M
Total Liabilities FY 2025 · Dec 31, 2025 $28.89M
Total Liabilities FY 2025 · Dec 31, 2024 $26.87M
Current Assets FY 2025 · Dec 31, 2025 $8.89M
Current Assets FY 2025 · Dec 31, 2024 $3.3M
Total Assets FY 2025 · Dec 31, 2025 $12.96M
Total Assets FY 2025 · Dec 31, 2024 $3.65M
Eps Basic FY 2025 · Dec 31, 2025 −$1.34
Eps Basic FY 2025 · Dec 31, 2024 −$2.36
Sga Expense FY 2025 · Dec 31, 2025 $13.06M
Sga Expense FY 2025 · Dec 31, 2024 $13.5M
Rd Expense FY 2025 · Dec 31, 2025 $3.78M
Rd Expense FY 2025 · Dec 31, 2024 $6.2M
Net Income FY 2025 · Dec 31, 2025 −$28.62M
Net Income FY 2025 · Dec 31, 2024 −$25.13M
Operating Income FY 2025 · Dec 31, 2025 −$16.22M
Operating Income FY 2025 · Dec 31, 2024 −$18.5M
Cost Of Revenue FY 2025 · Dec 31, 2025 $505K
Cost Of Revenue FY 2025 · Dec 31, 2024 $0
Revenue FY 2025 · Dec 31, 2025 $1.23M
Revenue FY 2025 · Dec 31, 2024 $0